GOSS earnings analysis
What we found in GOSS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q extract does not include current-quarter revenue, margins, EPS, cash flow, balance-sheet totals or segment results, so earnings trends cannot be assessed from the filing text supplied. The principal developments are the June 2026 debt exchange, a planned September 2026 seralutinib NDA despite PROSERA’s failure to meet its primary endpoint, and significant equity and warrant issuance. Liquidity and refinancing risk remain elevated because the company must maintain $40 million of liquidity and could face an accelerated March 2, 2027 maturity if more than $4.0 million of 2027 Notes remain outstanding.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls remain effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, and reported no material changes in internal control during the three months ended June 30, 2026.
- Debt exchange reshaped maturities
- Following the June 2026 Exchange Offer, the company had $18.948 million of 5.00% convertible notes due 2027 and $65.174 million of 7.50% secured convertible notes due 2030 outstanding.
- Seralutinib NDA remains targeted for 2026
- Management continues to plan a seralutinib NDA submission for September 2026 after a June 2026 FDA Type B meeting; the FDA characterized the PROSERA statistical significance and treatment effect as review issues rather than filing issues.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Debt maturities and liquidity pressure
- As of June 30, 2026, the company had $18.948 million of 2027 Notes, $65.174 million of 2030 Notes and approximately $134.8 million of other liabilities. The 2030 Notes require minimum liquidity of $40 million and may accelerate to March 2, 2027 if more than $4.0 million of 2027 Notes remain outstanding.
- PROSERA results threaten approval
- The Phase 3 PROSERA study did not meet its primary endpoint in February 2026. Although the company plans a September 2026 NDA, the FDA may reject the filing, require additional studies or decline approval based on the totality of the data, including PROSERA and the Phase 2 TORREY study.
- Substantial dilution overhang
- The June 2026 Exchange Offer resulted in issuance of 254,150,441 common shares, 33,402,727 prefunded warrants and 135,789,000 purchase warrants. The company also increased authorized common shares from 700,000,000 to 4,000,000,000 on July 14, 2026, leaving substantial potential for further dilution.
- Nasdaq minimum-bid compliance risk
- Nasdaq notified the company on April 8, 2026 that its bid price had been below $1.00 for 30 consecutive business days. The initial compliance period ends October 5, 2026, with a possible additional 180-day period subject to meeting other requirements.
What they said about what is next.
The provided 10-Q text contains no quantitative revenue or EPS guidance. Management plans to submit a seralutinib PAH NDA in September 2026; if accepted for filing, an FDA approval decision could occur in Q3 2027.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Gossamer Bio reported a significant increase in revenue for the first quarter of 2026, driven by collaboration with Chiesi, with revenue rising to $16.96 million, up from $9.89 million in the prior year. However, the…
- 10-K · March 17, 2026
- Gossamer remains a clinical‑stage biopharma focused on seralutinib; FY2025 revenue was $48.5M (all collaboration-related) while net loss widened to $170.4M and accumulated deficit reached $1,438.9M. The company reported…
- 10-Q · November 5, 2025
- Gossamer Bio reported Q3 revenue of $13.294M (up $3.814M vs. $9.480M in Q3 2024) while net loss widened to $48.2M for the quarter and $123.1M year-to-date. R&D investment increased (seralutinib R&D $45.542M in the…
- 10-Q · August 5, 2025
- Gossamer reported Q2 2025 revenue of $11.5 million versus $95.8 million in Q2 2024 (loss of the one-time license payment), and GAAP net loss of $38.3 million compared with net income of $49.2 million a year ago. R&D…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GOSS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever